الاتحاد الأوروبي - السلوفاكية - EMA (European Medicines Agency)

intervet international bv - inaktivovaného chimérneho kmeňa flavivírusov yf-wn - imunologické - kone - aktívnej imunizácie koní proti west nile virus (wnv) na zníženie klinických príznakov ochorenia a lézie v mozgu a na zníženie virému. nástup imunity: 2 týždne po primárnej vakcinácii dvoch injekcií. trvanie imunity: 12 mesiacov.

الاتحاد الأوروبي - السلوفاكية - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - mačací leukémia vírus rekombinantný canarypox vírus (vcp97) - immunologicals pre felidae, - mačky - aktívna imunizácia mačiek vo veku 8 týždňov alebo starších proti mačacej leukémii na prevenciu pretrvávajúcej virémie a klinických príznakov súvisiacej choroby. nástup imunity bol preukázaný 2 týždne po primárnej vakcinácii. trvanie imunity je jeden rok po poslednej vakcinácii.

الاتحاد الأوروبي - السلوفاكية - EMA (European Medicines Agency)

amgen europe b.v. - cinakalcet hydrochlorid - hypercalcemia; parathyroid neoplasms; hyperparathyroidism - homeostáza vápnika - sekundárne hyperparathyroidismadultstreatment stredných hyperparathyroidism (hpt) u dospelých pacientov s end štádiu ochorenia obličiek (esrd) na údržbu dialyzačnej terapie. pediatrické populationtreatment stredných hyperparathyroidism (hpt) u detí vo veku 3 rokov a staršie, v poslednom štádiu ochorenia obličiek (esrd) na údržbu dialyzačnej liečby v ktorých sekundárne hpt nie je primerane kontrolované s štandardnú starostlivosť terapia. mimpara sa môže použiť ako súčasť terapeutického režimu vrátane fosfát spojivá a/alebo vitamínu d a sterolov, podľa potreby. parathyroid karcinóm a primárnej hyperparathyroidism v dospelí. zníženie hypercalcaemia u dospelých pacientov s:parathyroid karcinóm;primárny hpt pre koho parathyroidectomy by byť označený na základe sérového vápnika v krvi (ako je definované príslušnými arl), ale v ktorých parathyroidectomy nie je klinicky vhodné alebo je kontraindikovaný.

الاتحاد الأوروبي - السلوفاكية - EMA (European Medicines Agency)

amgen europe b.v. - etelkalcetid hydrochlorid - hyperparatyroidizmus, sekundárny - anti-parathyroid agents, calcium homeostasis - parsabiv je indikovaný na liečbu sekundárnej hyperparatyreózy (prepravy) u dospelých pacientov s chronickou obličkovou chorobou (ckd) na hemodialýze terapia.

الاتحاد الأوروبي - السلوفاكية - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains) - immunologicals pre felidae, - mačky - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs. onsets of immunity isone week after primary vaccination course. the duration of immunity is one year after primary vaccination course and three years after the last re-vaccination.

الاتحاد الأوروبي - السلوفاكية - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline panleucopenia virus (pli iv) - immunologicals pre felidae, - mačky - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs. onset of immunity is one week after primary vaccination course the duration of immunity is one year after the primary vaccination course and three years after the last re-vaccination.

الاتحاد الأوروبي - السلوفاكية - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunologicals pre felidae, - mačky - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

الاتحاد الأوروبي - السلوفاكية - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - immunologicals pre felidae, - mačky - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs. následky imunitného systému boli preukázané jeden týždeň po primárnom očkovaní proti rhinotracheitíde, kalicivíru, chlamydophila felis a panleukopénii. the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

الاتحاد الأوروبي - السلوفاكية - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - immunologicals pre felidae, - mačky - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

الاتحاد الأوروبي - السلوفاكية - EMA (European Medicines Agency)

intervet international bv - tetanový toxoid - imunologické pomôcky pre koňovité - kone - aktívna imunizácia koní od veku 6 mesiacov proti tetanu, aby sa zabránilo úmrtnosti. nástup imunity: 2 týždňov po základnej očkovania courseduration imunity: 17 mesiacov po základných očkovaní, samozrejme, 24 mesiacov po prvom revaccination.